Dexcom makes glucose monitoring systems for patients with diabetes. I don't see Americans getting healthier any time soon, so demand for the company's products should remain high for the foreseeable future.
The stock is just breaking out of a high tight flag pattern. Technically, a high tight flag requires a move up of 100% or more, so DXCM comes up a little short on the initial surge. But the pullback inside the flag was very shallow - well below the 25% allowed in this setup. So for me, it balances out.
On the fundamental side, sales growth is accelerating. +23%, +25%, and +32% for the last three quarters. Earnings are also expected to jump by 40% in 2022.
The stop loss on this trade would be the just beneath the low of the flag at $487.00.
The stock is just breaking out of a high tight flag pattern. Technically, a high tight flag requires a move up of 100% or more, so DXCM comes up a little short on the initial surge. But the pullback inside the flag was very shallow - well below the 25% allowed in this setup. So for me, it balances out.
On the fundamental side, sales growth is accelerating. +23%, +25%, and +32% for the last three quarters. Earnings are also expected to jump by 40% in 2022.
The stop loss on this trade would be the just beneath the low of the flag at $487.00.
免責聲明
這些資訊和出版物並非旨在提供，也不構成TradingView提供或認可的任何形式的財務、投資、交易或其他類型的建議或推薦。請閱讀使用條款以了解更多資訊。
免責聲明
這些資訊和出版物並非旨在提供，也不構成TradingView提供或認可的任何形式的財務、投資、交易或其他類型的建議或推薦。請閱讀使用條款以了解更多資訊。